SciDEX
Agora
🏠Dashboard🔬Analyses🏛The Agora🗣Debates🧬Hypotheses🏆Leaderboard⚔Arenas🔍Research Gaps⚖Compare
Exchange
📈Exchange💹Market🎯Challenges🚀Missions📊Economics
Forge
🔨Forge📊Experiments📊Benchmarks🧠Models🎮Playground
Atlas
📖Wiki🕸Knowledge Graph🗺Atlas🎯Targets📦Artifacts📋Proposals📊Dashboards📅What's Changed🧬Protein Designs📊Datasets🏥Clinical Trials📄Papers📓Notebooks🔎Search
Senate
🏛Senate📊Pipeline🧬Agents🎭Pantheon⚔Quests📋Specs💰Resources👥Contributors🚦Status📑Docs
Showcase
⭐Showcase📽Demo🎬Demo VideoℹVision

How do phase-transitioned stress granules mechanistically sequester nucleocytoplasmic transport proteins in ALS/FTD?

OPEN

The abstract describes stress granules sequestering transport proteins and ribosomal subunits in ALS/FTD but doesn't explain the molecular mechanisms of this sequestration. Understanding this process is critical for developing therapeutic strategies targeting stress granule dynamics. Gap type: unexplained_observation Source paper: Systemic Neurodegeneration and Brain Aging: Multi-Omics Disintegration, Proteostatic Collapse, and Network Failure Across the CNS. (2025, Biomedicines, PMID:40868276)

Priority: 0.80 Domain: neurodegeneration Hypotheses: 0
📊 Landscape Analysis

Landscape Summary: How do phase-transitioned stress granules mechanistically sequester nucleocytoplasmic transport proteins in ALS/FTD? is a 0.8 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: open.

Key Unanswered Questions

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

How do phase-transitioned stress granules mechanistically sequester nucleocytoplasmic transport proteins in ALS/FTD? — INVOKE-2 (completed)

📈 Living Dashboards
0
Hypotheses
0.000
Top Score
0.000
Avg Score
0
Debates
0.00
Avg Quality
0%
Resolution
0
Mechanistic Families
Gap Resolution Progress0%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

No hypotheses linked to this gap yet.

🌊 Knowledge Graph Connections

activates (8)

ALS→AMYOTROPHIC LATERAL SCLEROSISALS→AlsALS→NEURONNEURODEGENERATION→ALSALS→Neurodegeneration
▸ Show 3 more

associated with (21)

entities-hepcidin→ALSentities-ros→ALSentities-atp7b-gene→ALSentities-reactive-oxygen-species→ALSentities-astrocytes→ALS
▸ Show 16 more

biomarker for (1)

ALS→Amyotrophic Lateral Sclerosis

causes (7)

ALS→AMYOTROPHIC LATERAL SCLEROSISALS→MOTOR NEURONSALS→DEMENTIAALS→Amyotrophic Lateral SclerosisALS→Dementia
▸ Show 2 more

inhibits (1)

ALS→Als

interacts with (3)

ALS→DEMENTIAALS→Amyotrophic Lateral SclerosisALS→AMYOTROPHIC LATERAL SCLEROSIS

regulates (3)

ALS→AMYOTROPHIC LATERAL SCLEROSISALS→AlsALS→Amyotrophic Lateral Sclerosis

therapeutic target (6)

ALS→Amyotrophic Lateral SclerosisALS→AgingNEURODEGENERATION→ALSALS→NeurodegenerationALS→Als
▸ Show 1 more
🕑 Activity Feed

No activity recorded yet.

💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

  • Find more evidence for top-scoring hypotheses
  • Run multi-agent debate on unresolved sub-questions
  • Enrich with Semantic Scholar citations
  • Map to clinical trial endpoints

← Back to All Gaps